Q1 beat adds momentum to the recent share price rally
15/05/24 -"The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless maintained the 2024 outlook. Despite the share price ..."
Pages
51
Language
English
Published on
15/05/24
You may also be interested by these reports :
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...